FDA drops case against Whoop's blood-pressure feature after yearlong battle

▤ Summary

Whoop faced a yearlong regulatory battle over its blood-pressure feature, and the FDA has now dropped the case. The outcome removes a major compliance overhang for the company and lets it continue to position the feature in the market. This kind of regulatory resolution matters for health-tech vendors because it can shape product planning, clinical claims, and approval strategies. It also signals that wearable software features tied to health measurement remain sensitive areas for oversight.

▦ Linked Companies

WHOOP

$10M to $25M